Omnicell, Inc. (OMCL)
NASDAQ • Healthcare
Last close at October 9, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Omnicell, Inc. keeps $8 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Oct 29
in 19 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Omnicell beat expectations on earnings while revenue came in line in the second fiscal quarter of 2026, reported July 30, 2026, with adjusted EPS of $0.94 topping the $0.47 estimate (+101%) as revenue of $312.2 million landed in line with the $310.2 million consensus (+0.6%). Revenue rose 7.4% to about $312.2 million (up from roughly $290.6 million a year ago), led by Connected devices, software licenses, and other at around $149.2 million, up 7.7% year over year, while SaaS and Expert Services contributed roughly $68.6 million, up 7.8%; geographically, the United States remained the largest market at about $281.0 million, up 6.7%, with Rest of world at roughly $31.2 million, up 15.0%. Profitability ran at a gross margin of 49.0% and an operating margin of 10.4%, with gross profit of about $152.9 million and operating income of roughly $32.4 million, and net income increased 330.7% to about $24.3 million (up from roughly $5.6 million a year ago). The company generated operating cash flow of about $69.5 million and repurchased roughly $0.4 million of stock. Next-period consensus calls for EPS of $0.42 on revenue of $304.4 million.
Next report — what to expect
Omnicell, Inc. (OMCL) reports next on October 29, 2026. Wall Street is looking for EPS of $0.42 on revenue of $304.4 million. For trailing context, revenue grew +7.4% year over year last quarter. OMCL has beaten EPS in 7 of 8 most recent quarters, putting focus on any repeat vs consensus.
About Omnicell, Inc.
Omnicell, Inc. (NASDAQ: OMCL) provides medication management technology and services for healthcare providers, combining automation, software, and pharmacy workflows across the medical information services area. The company generated $1.2 billion of revenue in FY2025 from hospital and health systems solutions, pharmacy platforms, and related support offerings.
Today's Snapshot
OMCL closed 2.8% higher at 35.82, in line with a firmer sector. Shares changed hands at about two-thirds of its usual level. Omnicell forecast weak operating profit.
Trading Volume
Below 10d avg (493.9K)
303K
vs S&P 500 Today
Outperforming Market
+2.25%
Updated: October 9, 2026 at 20:31 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$34.29 - $37.97Buy
- RSI (14)60.17Neutral
- Stochastic %K (14, 3, 3)82.37Sell
- MACD Level (12, 26)0.14Buy
Get premium market insights delivered directly to your inbox.